Champions Biotechnology has collaborated with Do-Coop for development of a more soluble form of SG410, its Benzoylphenylurea (BPU) sulfur analog compound.
Do-Coop has said that using Neowater, a proprietary water-based nanotechnology, it has been able to improve the solubility and activity of SG410.SG410, an antimitotic inhibitor that was shown in Biomerk Tumorgraft models to target microtubule associated protein tau (MAPT) deficient tumors.
Doug Burkett, president of Champions, said: We are excited to work with this innovative technology that enables us to move SG410 into Biomerk Tumorgraft testing and determine its optimal clinical application. We expect to have early Biomerk Tumorgraft results for SG410 by the end of 2009. Also, following nearly a year of efforts to build our oncology drug pipeline we expect to in-license additional drugs in the near future; SG410 is anticipated to be the first of many in-licensed compounds to enter Biomerk Tumorgraft evaluation.”
“Our Biomerk Tumorgraft technology enables identification of the most promising development path for the compound in terms of indication, drug combination, and target patient populations. Studies suggest that evaluations of compounds through Biomerk Tumorgrafts will lead to more efficient and successful clinical development, he added.
Eran Gabbai, president and CTO of Do-Coop, said: “Under the terms of the agreement, Do-Coop will receive development milestones and royalties based upon the clinical success of the compound. We are delighted to work with Champions and its groundbreaking Biomerk Tumorgraft platform. This technology should change the way in which cancer drugs are developed.
Virginia-based Champions Biotechnology is engaged in the development of preclinical platforms and tumor specific data of oncology drugs.
Israel-based Do-Coop Technologies is a private company that manufactures water-based materials using Nanotechnology for the biotechnology, pharmaceutical and chemical industries as well as additional industries.